Background-Takotsubo cardiomyopathy is an acute heart failure syndrome characterized 2
Introduction 1
There has been a rapid increase in the recognition of a syndrome of acute and severe, but 2 reversible, heart failure called Takotsubo or Stress cardiomyopathy, 1-3 also known as 3 'Broken Heart Syndrome', which usually follows within hours of an identifiable emotional, 4 psychological or physical stress. Takotsubo cardiomyopathy mimics symptoms of acute 5 myocardial infarction (MI), but is distinguished by the lack of coronary occlusion and by 6 characteristic regional wall motion abnormalities, classically a virtual apical ballooning 7 appearance due to a hypercontractile base of the heart relative to hypo-or akinetic apical 8 and mid left ventricular myocardium, the latter extending beyond a single coronary artery 9 territory.
1, 2 Initial recognition in earthquake survivors in Japan, plus the characteristic 10 ventricular shape, led to the 'Takotsubo' (meaning octopus-pot) label.
3, 4 It has become 11 apparent that ~1-2% of all presentations with suspected acute coronary syndrome cases are 12 finally diagnosed as Takotsubo cardiomyopathy. 3 
14
The pathophysiological mechanisms for this increasingly recognised syndrome are not 15 known. Evidence points to epinephrine as the precipitating factor. Physical or psychological 16 stress is a frequent precipitant, and serum catecholamine levels in Takotsubo patients 1-2 17 days after presentation are higher than those in patients with myocardial infarction with 18 pulmonary oedema: epinephrine falls back to MI levels only after 7-9 days. 1 Catecholamine 19 storms, more associated with epinephrine-secreting phaeochromocytomas than 20 norepinephrine-and dopamine-secreting phaeochromocytomas, 5 can also precipitate 21 Takotsubo cardiomyopathy. 6 Particularly, the reproduction of the signs of Takotsubo by 22 accidental administration of epinephrine (including single intramuscular 1mg doses from an 23 'Epi-pen') is most indicative of its central role. 7 Although there is a significant mortality in 24 responses were recorded using 2D echocardiography (Visualsonics Vevo 770) in the 10 parasternal long axis. Baseline scans were performed before catecholamine administration. 11
Preventative studies: a subgroup of animals were pretreated with the Gi protein inhibitor 12 pertussis toxin (PTX) (25μg.Kg -1), the p38MAP kinase antagonist SB203580 (0.1-10mg.Kg -1 ) 13 or the β 2 AR selective antagonist ICI 118,551 (1mg.Kg Rat cardiomyocyte isolation and  2 AR overexpression studies. Myocytes were isolated from 21 adult male Sprague-Dawley rats (Harlan, Bicester,UK; weight 250-350 grams) using the 22 standard enzymatic technique as described previously. 30 Isolated rat cardiomyocytes were 23 plated in culture medium at a field density of 10,000 cells/well and infected with either 1 Ad. 2 AR.GFP,  2 AR with mutations at the PKA phosphorylation sites 261, 262, 345, 346 S/A 2 ( 2 AR-PKA-KO) (Ad.β 2 AR-PKA-KO) or Ad.GFP (control) at a multiplicity of infection (MOI) of 3 500 for 48 hours. For pertussis toxin (PTX) treatment, Ad. 2 AR.GFP infected rat ventricular 4 myocytes were cultured in the presence or absence of PTX (1.5 µg/ml) for 48 hours. Survival 5 in culture was shown as a percentage of rod-shaped myocytes at the time of plating: >100 6 cells per well were counted, with triplicates for each condition.  2 AR-specific contractile 7 responses were measured on separately isolated apical and basal ventricular 8 cardiomyocytes using isoproterenol (100nM) plus the  1 AR selective antagonist CGP20712A 9 (300nM) (see supplementary methods).
21, 29

11
In vitro Takotsubo cardiomyopathy model. Freshly isolated rat ventricular cardiomyocytes 12 were perfused with epinephrine (1µM) for 20mins followed by washout (10min). A 13 subgroup of cells was preincubated with PTX for 3h at 35°C (1.5 µg.ml -1 obtained from failing human hearts at the time of heart transplantation; procedures for 7 collecting human heart tissues conformed to the Ethics Committee requirements of the 8 Royal Brompton and Harefield Hospital, UK. Written informed consent was provided by all 9 patients. The investigation conforms to the principles outlined in the Declaration of Helsinki. 10
Single human ventricular myocytes were isolated from explanted failing human hearts using 11 a standard enzymatic technique as described before. epinephrine (equivalent to ~5mg in an adult human). Intravenous bolus delivery was 6 selected to mimic the human physiological response to sudden high stress. Initial dose-7 response curves determined the highest catecholamine dose without excessive mortality 8 ( Figure S1 ). Epinephrine bolus triggered a rapid hypertensive response with reflex 9 bradycardia within seconds of administration, which stabilised back to normotension after 10 several minutes ( Figure S2 ), and was associated with an initial global increase in left 11 ventricular contractility (Figure 1 ). However, this dropped away to give a marked decrease 12 in cardiac contraction, initiating at 15 min and reaching a nadir between 20 and 25 min. 13
Contraction normalised within an hour. One defining characteristic of Takotsubo 14
Cardiomyopathy is the apical and mid-ventricular localisation of dysfunction, and this was 15
clearly reproduced in our model (Figure 1 ), and was confirmed by cardiac MRI ( Figure S3 and 16
Supplementary movie). 17 18
Apical hypokinesia is epinephrine-specific. We and others have previously reported that 19 epinephrine or isoproterenol at high concentrations can switch the  2 AR from positively 20 inotropic Gs to negatively inotropic Gi coupling, 17, 22, 33 while norepinephrine cannot. 16 We 21
found that equivalent high dose intravenous norepinephrine did not generate the negative 22 effect observed after epinephrine bolus ( Figure 1A-C) , and concentration-response curves 23 ( Figure S1 ) confirmed that no concentration of norepinephrine was negatively inotropic. 24
Changes in heart rate and systemic arterial blood pressure did not differ between 1 epinephrine and norepinephrine, indicating appropriate matching of effective 2 concentrations ( Figure S2 ). Lack of negative effect of norepinephrine additionally eliminates 3 either myocardial  1 AR, or  1 AR-mediated vasoconstriction as the principal mediator of the 4 epinephrine-stimulated negative inotropic effect. 5 6 Epinephrine-induced apical hypokinesia is Gi dependent. We used pertussis toxin (PTX) to 7 inhibit Gi by in vivo pre-treatment of the rats three days before the intravenous epinephrine 8 challenge. In vitro challenge of isolated cardiomyocytes from these hearts with carbachol 9 (after βAR stimulation) was used to verify inhibition of Gi effects (not shown). The negative 10 effect of epinephrine was completely abolished by PTX (Figure 2A We also developed an in vitro model, in which isolated rat ventricular cardiomyocytes were 22 treated for 20 min with epinephrine. These cells showed a decreased positive inotropic 23 response to a subsequent  2 AR challenge ( Figures 3A and S7) . Maximum responses to high 24 calcium were unchanged, indicating that overall cellular and contractile function was not 1 compromised ( Figure S8 ). The depression of β 2 AR response after epinephrine pretreatment 2 observed in this in vitro model was completely prevented (and the response became higher 3 than control) after PTX treatment ( Figures 3A and S7) . Notably, measurement of cAMP 4 under the same conditions showed much less marked changes: PTX treatment increased 5 contraction 11-fold without a significant increase in cAMP levels ( Figure 3B ). This implies a 6 parallel negative inotropic pathway activated through Gi. Since p38 MAPK has been shown 7 to be both Gi-dependent and negatively inotropic in rat ventricular myocytes we compared 8 treatment with PTX and a p38 MAPK inhibitor ( Figure 3C ). Both were able to increase β 2 AR 9 responses to a similar degree, and the effects of the two were not additive. 10
11
Apical ventricular cardiomyocytes have higher β 2 AR density and β 2 AR-mediated contractile 12
responses compared to basal cardiomyocytes. We have hypothesized that the increased 13 apical sensitivity observed in Takotsubo cardiomyopathy patients and our model is due to a 14 greater proportion of  2 ARs relative to  1 ARs in the apex, 8 since the greater concentration 15 of sympathetic innervation in the base of the heart 34 is counterbalanced by increased apical 16 AR functional responses to circulating catecholamines.
9-12 Using a radioligand binding-17 displacement assay to directly quantify the  2 : 1 AR ratio, we found that apical 18 cardiomyocytes demonstrated an increased  2 : 1 AR ratio ( Figure 3D ). The functional 19 consequences of a higher  2 : 1 AR ratio was studied and confirmed greater  2 AR-specific 20 contractile responses in apical ventricular cardiomyocytes compared to paired basal 21 cardiomyocytes isolated from the same heart ( Figure 3E ).  2 AR-dependent and maximal 22 cAMP responses demonstrated no difference between apical and basal cardiomyocytes 23 ( Figure S9 ), and therefore could not explain the observed gradient and contractile response. 24 1 Epinephrine-induced  2 AR-Gi signalling is cardioprotective. Since  2 AR-Gi is widely reported 2 to be antiapoptotic and cardioprotective, [35] [36] [37] we hypothesized that blocking  2 AR-Gi 3 signalling might increase the cardiotoxic effects of high epinephrine levels via uninhibited 4  1 AR-Gs and  2 AR-Gs signalling. In the rat Takotsubo model in vivo, epinephrine-induced 5 mortality was significantly increased by prior selective  2 AR-blockade with ICI 118,551 (at 6 concentrations insufficient to activate Gi) or p38MAPK inhibition with SB203580 ( Figure 4A ). 7
Death often occurred within 5-10 min, and was due to cardiogenic shock and hypokinesia 8 rather than primary ventricular fibrillation. In vitro, isoproterenol increased cell death in 9 cultured myocytes, an effect largely inhibited by  1 AR blockade ( Figure 4B ) while 10 overexpression of the  2 AR ( Figure 4B ) or Gi ( Figure 4C ) protected against catecholamine-11 induced cell death.  2 AR switching from Gs to Gi coupling is thought to be enhanced after 12 strong AR-Gs activation, mediated by cAMP-dependent protein kinase (PKA). 18 
13
Overexpression of a  2 AR construct in which PKA sites had been mutated to prevent 14 phosphorylation, not only failed to protect but produced  1 AR-independent cell death 15 ( Figure 4B ). This mutant was also unable to support β 2 AR-dependent negative inotropism, 16 in contrast to wild-type β 2 AR ( Figure S10 ). 17 18 -blockers which activate  2 AR-Gi do not rescue, and may worsen, established apical 19 hypokinesia. In the previous section we note that pretreatment with a specific β 2 AR blocker 20 before the epinephrine bolus did not appear to be a therapeutically useful manoeuvre. We 21 also predicted that clinically used β-blockers which activate β 2 AR-Gi might exacerbate the 22 epinephrine-induced negative inotropic effect. The Gi-dependent negative effect of β-23 blockers is most readily seen in myocytes from failing human hearts (where Gi is increased 1 29 ): we selected compounds that had either strong (propranolol) or modest (carvedilol) 2 effects on these cells ( Figure 5A ). Figures 5B-C show the effect of the two blockers added 15 3 min after epinephrine in the in vivo model, when peak negative responses are developing. 4
Propranolol, with higher  2 AR-Gi agonism, significantly enhanced and prolonged the 5 negative effects of epinephrine at both apex and base ( Figure 5B ), while carvedilol, with less 6 pronounced  2 AR-Gi agonism, had little effect on apex but converted the base from positive 7 to significant negative responses ( Figure 5C ). In contrast, the  1 AR-selective blocker 8 bisoprolol reduced the positive effect of epinephrine at the base but did not convert it to 9 significant negative response: there was no effect on the apical epinephrine response 10 ( Figure S11 ). These data support our hypothesis of synergistic effects of epinephrine with 11
propranolol (and to a minor extent carvedilol) upon  2 AR-Gi signalling. While the negative 12 inotropic of epinephrine was enhanced, there was no increase in mortality with the addition 13 of propranolol or carvedilol ( Figure 4A ). 14 15
Levosimendan reverses epinephrine-induced apical dysfunction without increased mortality. 16
Levosimendan was selected for comparison as it is an inotrope with a cAMP-independent 17 mechanism of action, increasing myofilament calcium sensitivity. 38 Global cardiac 18 contraction in untreated hearts was increased with infusion of this compound (not shown). 19
In contrast to other agents, application of levosimendan at the point where epinephrine 20 negative effects were beginning, was effective in preventing further decline in cardiac 21 function ( Figure 6 ). This contractile benefit and rescue occurred with no deaths in the 22 epinephrine-treated group ( Figure 4A) . Takotsubo cardiomyopathy is an increasingly recognised acute cardiac syndrome in the 2 modern era of early access to diagnostic coronary angiography. [1] [2] [3] As a cardiac response to 3 extreme stress levels it carries a relatively good prognosis, but has the intriguing feature of 4 regional (apical) hypokinesia, which is counterintuitive in relation to the systemic nature of 5 the trigger and the evolutionary drive for increased cardiac output during 'flight or fight ' 6 responses. We have developed a rat model mimicking the clinical features with acute, 7 reversible apical and mid-ventricular myocardial hypokinesia, but preserved or enhanced 8 basal contractility (Figure 1 ). Rapid high dose intravenous epinephrine bolus, designed to 9 mimic the serum catecholamine response to acute stress compared with the traditional 10 infusion protocols, recapitulated the classical clinical findings, whereas the equivalent 11 norepinephrine bolus did not (Figure 1 ). This implied the mechanism is epinephrine-specific, 12
and confirms the observation that dysfunction is not typically observed in the region with 13 the highest density of norepinephrine-releasing sympathetic nerve terminals. 13 
14
We have further investigated this concept of apical-basal gradients of catecholamine 15 responsiveness to AR subtype, and demonstrate that apical ventricular cardiomyocytes 16 have a higher  2 AR density and a greater  2 AR-induced sensitivity compared with basal 17 cardiomyocytes isolated from the same heart ( Figure 3D-E) . The inability of norepinephrine 18 at equivalent (and higher) doses to initiate acute apical dysfunction excludes coronary 19 vasospasm or  1 AR-mediated signalling as a primary effector (Figure 1 ). This agrees with 20 clinical observations that the apical dysfunction in Takotsubo cardiomyopathy extends 21 beyond the territory of a single coronary bed. [1] [2] [3] 8 Supporting the predominance of a 22 cardiomyocyte-based explanation rather than a vascular one is also the ability of our in vitro 23 cardiomyocyte model used here to reproduce a number of the key in vivo observations 1 (Figure 3) , as well as the matched responses of heart rate and blood pressure between 2 epinephrine and norepinephrine cohorts. 3
Norepinephrine also differs in that it does not couple  1 ARs or  2 ARs to Gi signalling, while 4 epinephrine at high concentrations produces a β 2 AR-Gs to Gi switch.  2 AR-Gi coupling has 5 been reported in a number of experimental models including β 2 AR and Gi overexpression, 6
and importantly in chronic heart failure, where Gi levels are increased.
29  2 AR-Gi coupling 7 occurs via a process termed stimulus/ligand-directed trafficking or biased agonism. Other 8 agonists such as high dose isoproterenol also produce this switch, and we note a study in 9 which isoproterenol infusion over 2 weeks also produced a specific apical contraction 10 defect. 9 The key role of Gi in the cardiodepression was shown by the ability of PTX to 11 convert apical responses to epinephrine from negative to positive (Figure 2 ). It should be 12 noted that the response of basal myocardium was also increased, implying that β 2 AR-Gi was The epinephrine-dependent  2 AR-Gi mediated negative inotropism requires a preceding 5 high  1 AR-Gs activation to initiate cAMP-dependent PKA-and GRK-phosphorylation of the 6  2 AR.
18, 41 This implies that, while norepinephrine does not directly couple receptors to Gi, 7 the rise in cAMP it produces will predispose the β 2 AR to traffic to Gi upon subsequent 8 epinephrine binding. Here we demonstrate that PKA-mediated  2 AR phosphorylation is 9 critical for Gi coupling as deleting the phosphorylation sites prevented both negative 10 inotropism and cardioprotection attributable to  2 AR-Gi coupling ( Figures 4B and S10 ). This 11 also explains the reversibility of the Takotsubo cardiomyopathy syndrome. As the serum 12 epinephrine levels fall,  2 AR dephosphorylation, or internalisation and replacement with de 13 novo unphosphorylated  2 ARs, would reduced the  2 AR-Gi stimulus trafficking and restore 14 normal contractile function in the surviving cardiomyocytes. Studies in model cell systems 15 overexpressing fluorescently labelled  2 AR demonstrate the dependence of both PKA-and 16 GRK-mediated  2 AR phosphorylation for  2 AR internalisation from the surface membrane 17 and recycling to different surface microdomains.
19 Interestingly they also demonstrate the 18 epinephrine-specific dependence of this trafficking. 41 This is relevant to the Takotsubo 19 cardiomyopathy patients as to date there has been failure to identify any associated 20 polymorphisms in the α 1 ARs, β 1 AR or β 2 ARs, 42 but one study, albeit with small patient 21 numbers, found an increased prevalence of the GRK polymorphism L41Q in the Takotsubo 22 cardiomyopathy patient cohort compared to healthy matched controls. 20 This is a 'gain-of-23 function' mutation, previously referred to as genetic betablockade, 43 confers reduced 1 responsiveness to AR agonists, and improved prognosis in the population carrying this 2 polymorphism, 43 both conceivably consistent with enhanced myocardial  2 AR-Gi coupling. 3 4 Although the final outcome for the Takotsubo patient is generally good, they have been 5 through an acute cardiac event requiring hospitalisation, and there is a significant incidence 6 of cardiogenic shock (~4%), malignant ventricular arrhythmias (1-2%) and death (1-1.5%). It 7 therefore seemed reasonable to try to block the depression of contraction with either a 8 specific β 2 AR antagonist or a p38 MAPK inhibitor. However the marked increase in mortality 9 produced by this manoeuvre gave a clear indication that this was a counterproductive 10 strategy ( Figure 4A ). The rapidity of the death, usually within 5-10 and always within 45 11 min, made it unlikely that apoptosis was the underlying mechanism. The β 2 AR and/or Gi 12 have been implicated in suppression of arrhythmias, 44 and β 2 AR variants with sudden 13 cardiac death.
45 β 2 AR knockout mice went into cardiogenic shock following doxorubicin, 14 through a β 1 AR-related mechanism 46 and β 2 AR/Gi mechanisms have also been implicated in 15 post-ischemic stunning. 47 All these are potential mechanisms which could underlie the acute 16 mortality. We suggest that the enhanced  2 AR-Gi coupling initiated by high epinephrine 17 levels is protective to dampen the effects of toxic AR-Gs coupling, which is left unchecked 18 would be fatal. 19
20
Few β-blockers are pure neutral antagonists, with most having some other effect such as 21 partial agonism (intrinsic sympathomimetic activity), inverse agonism (reduction in activity 22 of constitutively active receptors) or biased agonism (ligand directed trafficking to other 1 pathways). It has been amply demonstrated that blockers of the β 2 AR can activate other 2 signalling pathways, both G-protein and non-G-protein-dependent. 48 We were first alerted 3 to the possibility that the cardiodepressant effects in Takotsubo Cardiomyopathy were 4 β 2 AR-Gi dependent by their similarity to the β 2 AR-Gi-mediated effect of β-blockers on 5 myocytes from failing human heart. 29 We therefore hypothesised that β-blockers with 6 strong β 2 AR-Gi agonism would synergise with the negative inotropic effect of epinephrine. 7
Propranolol, a particularly cardiodepressant agent, markedly enhanced and prolonged the 8 negative phase when given after the epinephrine bolus in our in vivo model ( Figure 5B ). In 9 support of the hypothesis of additive negative inotropic effects of propranolol and 10 epinephrine, we note a recent report that an acute dilated cardiomyopathy was precipitated 11 in a patient with phaeochromocytoma upon taking propranolol for migraine. 49 Carvedilol 12 had a more modest effect, reversing the basal hypercontractility whilst having a neutral 13 effect upon the apical hypokinesia ( Figure 5C ). Carvedilol (and propranolol) are also able to 14 produce biased agonism through Gβγ mechanisms, 50 which would be PTX sensitive. 15
Although possibly exacerbating the syndrome, carvedilol could be useful in treatment in the 16 minority of Takotsubo cardiomyopathy patients with severe left ventricular outflow tract 17 obstruction secondary to the basal hypercontractility. It should be noted that neither 18 blocker had a deleterious effect on mortality in the Takotsubo Cardiomyopathy model. 19
Bisoprolol, which is predominantly β 1 AR selective, did not reproduce these effects to 20 synergise with epinephrine. 21
22
We considered the implications for treating Takotsubo cardiomyopathy, and for heart 1 failure therapy more generally. For the Takotsubo patient, strategies to raise cAMP 2 (catecholaminergic inotropes or phosphodiesterase inhibitors) would clearly be 3 contraindicated. Indeed dobutamine administered for stress echocardiography testing has 4 precipitated Takotsubo Cardiomyopathy.
7 A cAMP-independent inotrope, levosimendan, 5 was effective in reversing the negative inotropic effect of epinephrine and rescue occurred 6 without increased (and a trend to decreased) mortality (Figures 4A and 6 ). We suggest that 7 this is likely to be a safe supporting and bridging strategy for the sickest patients with 8 cardiogenic shock until spontaneous recovery occurs, and preliminary clinical reports 9 support this view. 51, 52 It should be noted that at the higher doses levosimendan can inhibit 10 phosphodiesterases, 38 and increase cAMP, and thus we only would recommend the lower 11 (non-vasodilatory) doses. The value of non-selective -blockers, which may also act as 12 agonists at  2 AR-Gi, is more difficult to predict, since they may amplify both the negative 13 inotropic and the protective effects of epinephrine. It could further be suggested that the 14 beneficial effects of β-blockers in heart failure has taken serendipitous advantage of 15 cardioprotective β 2 AR-Gi biased agonism. If those two effects could be modulated 16 separately, this might point the way for an improved design of future -blockers by selecting 17 for cardioprotection through  2 AR-Gi biased agonism. 
